Bioequivalence and Bioavailability Forum

Dear Hermann!

thank u so much for your reply...

One more clarrification please....U said Proc Mixed is for >2treatments
but FDA guideline "Statistical Approaches to Establishing Bioequivalence" says PROC MIXED in SAS should be used for the analysis of replicated crossover studies for average BE[p.13]. Is there any particular reason behind this? .

Because 2 treatment 4 period design is a replicate crossover design. I compare a sample data set of 2x4 design with missing values (example 4.4 in the text "BIOEQUIVALENCE and STATISTICS in CLINICAL PHARMACOLOGY") using both GLM and MIXED procedure. both will give same output. then why FDA says to use MIXED procedure for replicate crossover design?. Any reason?.....

someone says GLM procedure deletes the entire subject from an analysis if that person has any missing data,but MIXED does not. Is it correct?

Regards


Matz